跳至主要内容
临床试验/NCT01017549
NCT01017549已完成不适用

Post Market Clinical Study to Evaluate the Safety and Performance of the Axxent® Electronic Brachytherapy System in Women With Resected, Early Stage Breast Cancer

Xoft, Inc.20 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2007年3月26日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Xoft, Inc.
入组人数
44
试验地点
20
主要终点
Number of Participants With Delivery of 34 Gy in 10 Fractions

研究概览

简要总结

The purpose of this multi-center clinical study is to compile post market performance and safety data on the Axxent System.

详细描述

The purpose of this multi-center clinical study is to compile post market performance and safety data on the Axxent System for the delivery of radiation therapy as part of breast conserving therapy in women with resected, early stage breast cancer.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Age >50 years
  • Tumor with Tis, T1, N0, M0 - (AJC Classification)
  • Invasive ductal carcinoma or ductal carcinoma in situ
  • Negative microscopic surgical margins of at least 1mm in all directions
  • Adequate skin spacing between balloon surface and surface of the skin - (> 7mm)

排除标准

  • Pregnancy or breast-feeding - (During the treatment portion of the study, sexually active women of childbearing age will be asked to use pregnancy prevention)
  • Scleroderma, systemic sclerosis and active lupus
  • Infiltrating lobular histology

结局指标

主要结局

Number of Participants With Delivery of 34 Gy in 10 Fractions

时间窗: measured at end of 10th fraction, usually within 7 days

Successful delivery of the radiation treatment defined as a total 34 Gy in a total of 10 fractions, 3.4 Gy per fraction. (Gray = GY is a measure of radiation dose delivered to tissue)

次要结局

  • Serious Adverse Device Related Events Reported During the Course of the Study Through 6 Month Follow-up.(Through 6 months)

研究者

发起方
Xoft, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (20)

Loading locations...

相似试验